Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: A meta-analysis

Biphasic Insulin Aspart 30 in Insulin-Naive People with Type 2 Diabetes in Non-western Nations: Results from a Regional Comparative Multinational Observational Study (A1chieve)

“…[5][6][7] Analyses and reviews of randomized clinical trials (RCTs) of insulin analogs confirm that they can help achieve and maintain good blood glucose (BG) control, while reducing the hypoglycemia risk and improving tolerability and/or quality of life (QoL). 8,9 However, given the global diversity in diabetes care resources, 10,11 it is important to know if RCT findings are replicated under regular clinical conditions in a broader range of countries/ethnicities.…”

Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

“…BIAsp 30 is well-tolerated in patients with type 2 diabetes and a recent meta-analysis of nine RCTs concluded that it is associated with lower rates of nocturnal and major hypoglycemia compared with BHI 30, but with a higher rate of daytime hypoglycemia 16 . Given the risk of hypoglycemia, there is a clear need to monitor the safety of switching from BHI to BIAsp in patients with type 2 diabetes.…”

A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus

“…BIA30 was found to be more effective in the treatment of patients with a high baseline HbA1c level, enabling most patients to achieve glycemic control (14). BIA30 has additionally been shown to improve glycemic control subsequent to the failure of diet, exercise and oral antidiabetic agents (15); however, the side effects of the drug are evident and BIA30 therapy can increase the risk of daytime hypoglycemia (16).…”